Core Insights - The company reported third-quarter revenue of 303 million yuan, representing a year-on-year increase of 7.94% [1] - The net profit for the third quarter was a loss of 16.7865 million yuan [1] - For the first three quarters, the company achieved a revenue of 843 million yuan, reflecting a year-on-year growth of 5.14% [1] - The net profit for the first three quarters was a loss of 29.6849 million yuan [1]

Core Points - Shanghai Medicilon Inc. (the "Company") announced that shareholder Lin Changqing has released a portion of his pledged shares [2] - Lin Changqing holds a total of 4,113,654 shares, representing 3.06% of the Company's total equity [2] - The release involves 1,050,000 shares, leaving Lin with 2,400,000 pledged shares, which is 58.34% of his total holdings and 1.79% of the Company's total equity [2] Summary of Events - The Company received notification from shareholder Lin Changqing regarding the completion of the share pledge release [2] - The data provided is based on the shareholding as of October 24, 2025 [2] - The Company will fulfill its information disclosure obligations in case of any significant changes regarding the pledge [3]

证券代码：688202 证券简称：美迪西 公告编号：2025-065 上海美迪西生物医药股份有限公司 2025 年员工持股计划完成股票非交易过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 27 日，公司收到中国证券登记结算有限责任公司出具的《证 券过户登记确认书》，确认公司回购专用证券账户（证券账户号码：B886178428） 所持有的 1,371,948 股公司股票已于 2025 年 10 月 24 日非交易过户至"上海美迪 西生物医药股份有限公司－2025 年员工持股计划"证券账户（证券账户号码： B887678926），过户价格为 17.45 元/股。截至本公告披露日，本员工持股计划证 券账户持有公司股份数量为 1,371,948 股，占公司当前总股本的比例为 1.02%。 根据《上海美迪西生物医药股份有限公司 2025 年员工持股计划（草案）》 的相关规定，本员工持股计划的存续期不超过 24 个月，所获标的股票的锁定期 为 12 个月，自公司公告最后一笔标的股票过户至本员工持股计 ...

公司于近日接到股东林长青通知，获悉其所持有公司的部分股份办理了解除 质押手续，具体事项如下： | 股东名称 | 林长青 | | --- | --- | | 本次解除质押股份 | 股 1,050,000 | | 占其所持股份比例 | 25.52% | | 占公司总股本比例 | 0.78% | | 解除质押时间 | 年 月 日 2025 10 23 | | 持股数量 | 4,113,654 股 | 一、 本次股份解除质押情况 1 | 持股比例 | 3.06% | | --- | --- | | 剩余被质押股份数量 | 股 2,400,000 | | 剩余被质押股份占其所持股份比例 | 58.34% | | 剩余被质押股份占公司总股本比例 | 1.79% | 证券代码：688202 证券简称：美迪西 公告编号：2025-064 上海美迪西生物医药股份有限公司 关于股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 上海美迪西生物医药股份有限公司（以下简称"公司"）股东林长青持有 公司股份 ...

Group 1 - Medisi announced that shareholder Lin Changqing holds approximately 4.11 million shares, accounting for 3.06% of the total share capital [1] - After the release of the pledge, Lin Changqing has pledged a total of 2.4 million shares, which is 58.34% of his total holdings and 1.79% of the company's total share capital [1] - For the year 2024, Medisi's revenue composition is projected to be 99.96% from preclinical CRO business and 0.04% from other businesses [1] Group 2 - As of the report, Medisi's market capitalization is 9.3 billion yuan [1]

证券之星消息，10月27日医疗服务板块较上一交易日上涨1.63%，美迪西领涨。当日上证指数报收于 3996.94，上涨1.18%。深证成指报收于13489.4，上涨1.51%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688202 | 美迪西 | 69.18 | 8.98% | 9.15万 | | 6.20亿 | | 688710 | 益诺思 | 45.45 | 5.89% | 2.31万 | | 1.03亿 | | 600721 | 百花医药 | 9.63 | 5.13% | 27.20万 | | 2.59亿 | | 301509 | 美凯生科 | 38.30 | 5.08% | 6.29万 | | 2.41亿 | | 002173 | 创新医疗 | 24.59 | 5.00% | 84.81万 | | 20.77亿 | | 301257 | 曾感斯 | 45.48 | 4.79% | 2.76万 | | 1.25亿 | | 603127 | ...

Core Points - Meidi Xi (688202.SH) reported a revenue of 540.4 million yuan for the first half of 2025, representing a year-on-year growth of 3.64% [1][3] - The net profit attributable to shareholders was -12.9 million yuan, and the net profit after deducting non-recurring gains and losses was -26.7 million yuan [1][3] - The net cash flow from operating activities was 74.67 million yuan [1][3] Financial Data Summary - Revenue for the first half of 2025: 540.4 million yuan, compared to 521.4 million yuan in the same period last year, an increase of 3.64% [3] - Total profit for the period was -20.55 million yuan, an improvement from -90.03 million yuan year-on-year [3] - The net profit attributable to shareholders was -12.9 million yuan, compared to -70.23 million yuan in the previous year [3] - The net profit after deducting non-recurring gains and losses was -26.73 million yuan, compared to -79.60 million yuan last year [3] - The net cash flow from operating activities improved to 74.67 million yuan from -47.52 million yuan in the same period last year [3] Historical Financial Performance - In 2023 and 2024, the net profit attributable to shareholders is projected to be -33.21 million yuan and -331 million yuan, respectively [3] - Revenue for 2024 is expected to be 1.04 billion yuan, down 24.01% from 1.37 billion yuan in 2023 [5] - The net profit attributable to shareholders for 2024 is projected at -330.85 million yuan, compared to -33.21 million yuan in 2023 [5] Fundraising and IPO Information - Meidi Xi raised a total of 643.25 million yuan through its IPO, with a net amount of 578.75 million yuan after expenses [6] - The company initially planned to raise 346.91 million yuan for various projects, including drug research and working capital [6] - The total fundraising from two rounds of financing amounts to 1.643 billion yuan [9]

Group 1 - The core viewpoint is that the A-share innovative drug concept stocks are experiencing a significant upward trend, with notable increases in stock prices for several companies [1] - Iwubio has seen a rise of over 10% in its stock price [1] - Haoyuan Pharmaceutical has increased by over 9% [1] - Other companies such as Fuxiang Pharmaceutical, Changshan Pharmaceutical, and Medici have also shown upward movement in their stock prices [1]

Group 1 - The core point of the news is that Meidisi's stock price increased by 5.2% to 63.97 CNY per share, with a trading volume of 166 million CNY and a market capitalization of 8.595 billion CNY as of the report date [1] - Meidisi, established on February 2, 2004, and listed on November 5, 2019, is located in the Pudong New Area of Shanghai and specializes in providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes 50.34% from preclinical research, 49.64% from drug discovery and pharmaceutical research, and 0.01% from other supplementary services [1] Group 2 - From the perspective of fund holdings, one fund under the Fortune Fund has a significant position in Meidisi, specifically the Fortune SSE Index ETF Link A/B (100053), which held 400 shares in the second quarter, unchanged from the previous period, representing 0.0002% of the circulating shares [2] - The Fortune SSE Index ETF Link A/B (100053) was established on January 30, 2011, with a latest scale of 274 million CNY, and has achieved a year-to-date return of 15.79%, ranking 2944 out of 4218 in its category [2] - The fund managers, Wang Baohe and Fang Min, have tenures of 14 years and 10 years respectively, with Wang managing assets totaling 9.06 billion CNY and Fang managing 25.209 billion CNY [2]

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]